

1 **Role of Cardiorespiratory Fitness and Mitochondrial Energetics in Reduced Walk Speed of**  
2 **Older Adults with Diabetes in the Study of Muscle, Mobility and Aging (SOMMA)**

3 Sofhia V. Ramos<sup>1</sup>, Giovanna Distefano<sup>1</sup>, Li-Yung Lui<sup>2,3</sup>, Peggy M. Cawthon<sup>2,3</sup>, Philip Kramer<sup>4</sup>,  
4 Ian J. Sipula<sup>6</sup>, Fiona M. Bello<sup>6</sup>, Theresa Mau<sup>2,3</sup>, Michael J. Jurczak<sup>6</sup>, Anthony J. Molina<sup>5</sup>, Erin E.  
5 Kershaw<sup>6</sup>, David J. Marcinek<sup>7</sup>, Frederico G.S. Toledo<sup>6</sup>, Anne B. Newman<sup>6</sup>, Russell T. Hepple<sup>8</sup>,  
6 Stephen B. Kritchevsky<sup>4</sup>, Bret H. Goodpaster<sup>1</sup>, Steven R. Cummings<sup>2,3</sup>, Paul M. Coen<sup>1</sup>

7 Affiliations:

8 <sup>1</sup>Translational Research Institute, Advent Health, Orlando, Florida, USA.

9 <sup>2</sup>San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San  
10 Francisco, California USA.

11 <sup>3</sup>Department of Epidemiology and Biostatistics, University of California, San Francisco,  
12 California, USA.

13 <sup>4</sup>Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North  
14 Carolina, USA.

15 <sup>5</sup>Department of Medicine, University of California, San Diego, California, USA.

16 <sup>6</sup>Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine,  
17 University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

18 <sup>7</sup>Department of Radiology, University of Washington School of Medicine, Seattle, Washington,  
19 USA.

20 <sup>8</sup>Department of Physical Therapy, University of Florida, Gainesville, Florida, USA.

21

22 Email addresses: [Sofhia.ramos@adventhealth.com](mailto:Sofhia.ramos@adventhealth.com), [Giovanna.distefano@adventhealth.com](mailto:Giovanna.distefano@adventhealth.com),  
23 [lily.lui@ucsf.edu](mailto:lily.lui@ucsf.edu), [peggy.cawthon@ucsf.edu](mailto:peggy.cawthon@ucsf.edu), [pkramer@wakehealth.edu](mailto:pkramer@wakehealth.edu), [iansipula@pitt.edu](mailto:iansipula@pitt.edu),  
24 [fiona.bello@epfl.ch](mailto:fiona.bello@epfl.ch), [Theresa.Mau@ucsf.edu](mailto:Theresa.Mau@ucsf.edu), [jurczakm@pitt.edu](mailto:jurczakm@pitt.edu), [ajmolina@health.ucsd.edu](mailto:ajmolina@health.ucsd.edu),  
25 [kershawee@upmc.edu](mailto:kershawee@upmc.edu), [dmarc@uw.edu](mailto:dmarc@uw.edu), [toledofgs7@pitt.edu](mailto:toledofgs7@pitt.edu), [anewman@pitt.edu](mailto:anewman@pitt.edu),  
26 [rthepple@php.ufl.edu](mailto:rthepple@php.ufl.edu), [skritche@wakehealth.edu](mailto:skritche@wakehealth.edu), [bret.goodpaster@adventhealth.com](mailto:bret.goodpaster@adventhealth.com),  
27 [steven.cummings@ucsf.edu](mailto:steven.cummings@ucsf.edu)

28

29 Correspondence:

30 Paul M. Coen, PhD

31 AdventHealth, Orlando

32 Translational Research Institute

33 765-426-9743

34 paul.coen@adventhealth.com

35

36 Key Words: Diabetes, Aging, Cardiorespiratory Fitness, Mitochondrial Energetics, Walking  
37 Speed

38 Word count = 3954, Tables = 3, Figures = 1

39

40

41 **ABSTRACT**

42

43 **Rationale** – Cardiorespiratory fitness and mitochondrial energetics are associated with reduced  
44 walking speed in older adults. The impact of cardiorespiratory fitness and mitochondrial  
45 energetics on walking speed in older adults with diabetes has not been clearly defined.

46 **Objective** – To examine differences in cardiorespiratory fitness and skeletal muscle  
47 mitochondrial energetics between older adults with and without diabetes. We also assessed the  
48 contribution of cardiorespiratory fitness and skeletal muscle mitochondrial energetics to slower  
49 walking speed in older adults with diabetes.

50 **Findings** – Participants with diabetes had lower cardiorespiratory fitness and mitochondrial  
51 energetics when compared to those without diabetes, following adjustments for covariates  
52 including BMI, chronic comorbid health conditions, and physical activity. 4-m and 400-m  
53 walking speeds were slower in those with diabetes. Mitochondrial oxidative capacity alone or  
54 combined with cardiorespiratory fitness mediated ~20-70% of the difference in walk speed  
55 between older adults with and without diabetes. Further adjustments of BMI and co-morbidities  
56 further explained the group differences in walk speed.

57 **Conclusions** – Skeletal muscle mitochondrial energetics and cardiorespiratory fitness contribute  
58 to slower walking speeds in older adults with diabetes. Cardiorespiratory fitness and  
59 mitochondrial energetics may be therapeutic targets to maintain or improve mobility in older  
60 adults with diabetes.

61

62

63

64

65

66

67

68

69

70

71

72

73

74 **ARTICLE HIGHLIGHTS**

75 Why did we undertake this study?

- 76 • To determine if mitochondrial energetics and cardiorespiratory fitness contribute to  
77 slower walking speed in older adults with diabetes.

78 What is the specific question(s) we wanted to answer?

- 79 • Are mitochondrial energetics and cardiorespiratory fitness in older adults with diabetes  
80 lower than those without diabetes? How does mitochondrial energetics and  
81 cardiorespiratory fitness impact walking speed in older adults with diabetes?

82 What did we find?

- 83 • Mitochondrial energetics and cardiorespiratory fitness were lower in older adults with  
84 diabetes compared to those without diabetes, and energetics, and cardiorespiratory  
85 fitness, contributed to slower walking speed in those with diabetes.

86 What are the implications of our findings?

- 87 • Cardiorespiratory fitness and mitochondrial energetics may be key therapeutic targets to  
88 maintain or improve mobility in older adults with diabetes.

## 89        **Introduction**

90        The US population is rapidly aging, and in 2022 the percentage of Americans aged 65 and  
91 older diagnosed with diabetes remains high at 30% [1]. This represents a healthcare challenge as  
92 older adults with diabetes have a greater risk of cardiovascular disease and mobility disability [2,  
93 3]. The contributors to impaired mobility in older individuals with diabetes include the presence  
94 of co-morbidity, increased body mass index (BMI) [4], and lower muscle strength and quality [5-  
95 7]. However, the relationship between diabetes and loss of mobility remains only partially  
96 explained, and other contributors also likely play a role. Our group and others reported that  
97 cardiorespiratory fitness and skeletal muscle mitochondrial energetics are linked to reduced  
98 walking speed in aging, which is a predictor of mobility disability [8-10]. For example, muscle  
99 bioenergetics assessed using  $^{31}\text{P}$ -MRS was highly correlated with walking speed and partially  
100 explained age-related poorer performance in short (6-m) and long (400-m) walking tasks [10].  
101 Several studies have found a close relationship between cardiorespiratory fitness and walking  
102 speed in older adults [11], which suggests that the decline in aerobic capacity also contributes to  
103 slower walking speed and mobility disability with age.

104        Muscle biopsies from individuals with diabetes have been shown to have lower oxidative  
105 phosphorylation (OXPHOS) capacity compared with muscle from healthy controls [12-14].  
106 However, some studies [15, 16], but not all [12, 13, 17], indicate no differences between patients  
107 with diabetes and BMI-matched controls, indicating that obesity *per se* may underlie the lower  
108 muscle oxidative capacity. Indeed, other studies in people without diabetes have shown that BMI  
109 is strongly related to muscle oxidative capacity [18]. In addition, reports assessing mitochondrial  
110 energetics in older adults with diabetes tend to have small sample size and lack adjustment for  
111 critical confounding variables including physical activity and adiposity [13, 14, 17], and there are

112 few reports focusing on older adults with diabetes specifically. Lower fitness is a predictor of  
113 insulin resistance and diabetes [19], and prevalence of diabetes is greater in individuals with low  
114 fitness [20]. It is unknown whether diabetes associated changes in cardiorespiratory fitness  
115 and/or muscle energetics explain slower walking speed seen in people with diabetes, independent  
116 of other covariates.

117         In this analysis, we leveraged data from the Study of Muscle, Mobility and Aging  
118 (SOMMA) [21], to investigate the association of diabetes with cardiorespiratory fitness and  
119 mitochondrial energetics in a cohort of 879 older adults who were well phenotyped in terms of  
120 the free living physical activity behaviors and body composition. We utilized <sup>31</sup>P-MRS, to  
121 measure muscle mitochondrial energetics *in vivo* (ATPmax) and high-resolution respirometry to  
122 measure mitochondrial energetics in muscle biopsies, a complementary approach that  
123 interrogates mitochondrial OXPHOS capacity at the myocellular level. Here, we tested the  
124 hypothesis that diabetes would be associated with lower cardiorespiratory fitness and muscle  
125 energetics independent of adiposity, physical activity levels, chronic comorbid health conditions,  
126 and oral hypoglycemic medication use. We also tested whether cardiorespiratory fitness and  
127 mitochondrial energetics mediate slower walking speed of older adults with diabetes.

## 128 **RESEARCH DESIGN AND METHODS**

### 129 **Participant Recruitment**

130         The Study of Muscle Mobility and Aging (SOMMA; <http://sommaonline.ucsf.edu>) is a  
131 prospective longitudinal cohort study of older adults and was designed to understand the  
132 biological basis of muscle aging [21]. Men and women (70+ yrs. old) were recruited between  
133 April 2019 to December 2021. Participants were enrolled at University of Pittsburgh and Wake

134 Forest University School of Medicine if they were willing and able to complete a skeletal muscle  
135 biopsy and undergo Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS). Exclusion  
136 criteria included an inability to walk one-quarter of a mile or climb a flight of stairs; had a  
137 BMI>40kg/m<sup>2</sup>; had an active malignancy or dementia; or any medical contraindication to biopsy  
138 or MR. Finally, participants must have been able to complete the 400-m walk test; those who  
139 appeared as they might not be able to complete the 400-m walk at the in-person screening visit  
140 completed a short distance walk (4-m) to ensure their walking speed was  $\geq 0.6$ m/s. Presence of  
141 diabetes was identified by self-report, use of prescribed hypoglycemic medication, or having an  
142 HbA1c  $\geq 6.5\%$ . WIRB-Copernicus Group (WCG) Institutional Review Board (WCGIRB, study  
143 number 20180764) approved the study as the single IRB and all participants provided written  
144 informed consent.

#### 145 **Baseline Assessments**

146 Detail on study design and methodology have been published elsewhere [21]. The  
147 SOMMA Baseline Visit generally consisted of three days of assessments over several weeks: on  
148 “Day 1” the 400-m walk plus most other in-person assessments; “Day 2” cardiopulmonary  
149 exercise testing (CPET) and Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) were  
150 assessed; “Day 3” muscle biopsy specimen was collected. Age, sex, and race were collected by  
151 self-report. The self-reported medical conditions (heart disease, stroke, kidney disease/renal  
152 failure, and peripheral vascular disease) were assessed to determine if participants had those  
153 conditions or not. Participants were asked to bring all prescription medications they had taken in  
154 the 30 days prior to their “Day 1” clinic visit. If a participant forgot to bring one or more  
155 medications, clinic staff obtained this information over the telephone or at the return visit. The  
156 prescription medication use was reviewed and updated at the additional baseline visit days where

157 CPET and tissue sampling were done. Body weight, height, and physical function assessments  
158 were also measured and accelerometry devices were provided. Most SOMMA participants  
159 completed cardiopulmonary exercise testing (CPET), magnetic resonance spectroscopy (MRS)  
160 and provided a percutaneous biopsy of the vastus lateralis muscle which was performed under  
161 fasted conditions. On the day of the muscle biopsy, participants prescribed oral hypoglycemic  
162 medication were asked to take their medications following tissue sampling.

### 163 **Mobility Assessments**

164 Mobility was assessed by 400m and 4m walking tests. For the 400-m walk test,  
165 participants were instructed to walk 10 complete laps around a set course at their usual pace and  
166 without overexerting themselves. 4m walking speed was measured in 2 trials and the  
167 participant's best time was used to calculate walking speed in m/sec.

### 168 **Physical Activity Assessments**

169 Two devices were used to assess activity: the thigh-worn activPal that recorded total  
170 daily step count and the wrist-worn ActiGraph GT9x. Devices were placed on the participants at  
171 the baseline "Day 1" visit with a data collection period of 7 full days. Data was included only if  
172 the device was worn over a 24-hour period and had  $\geq 17$  hour per day wear time. Activity levels  
173 collected from ActiGraph were determined by cut points described by Montoye and colleagues  
174 [22], and included total daily physical activity time, and time spent in sedentary, light, and  
175 moderate to vigorous physical activity (MVPA).

### 176 **Cardiopulmonary Exercise Testing Assessment**

177 Participants walked for 5 minutes at a preferred walking speed, and progressive  
178 symptom-limited exercise protocol ensued with increases in speed (0.5 mph) and incline (2.5%)

179 in 2-minute increments using a modified Balke protocol or a manual protocol [23, 24].

180 Cardiorespiratory fitness was determined as  $VO_{2peak}$  (mL/min) which was identified as the  
181 highest 30-second average of  $VO_2$  (mL/min) achieved.

## 182 **Magnetic Resonance (MR) Imaging and Spectroscopy**

183  $^{31}P$ Phosphorous-MRS was used to assess *in-vivo* mitochondrial adenosine triphosphate  
184 (ATP) generation in the quadriceps muscle during an acute bout of knee isometric extension  
185 exercise [21, 24] . A 3 Tesla magnetic resonance magnet (Siemens Medical Systems – Prisma  
186 [Pittsburgh] or Skyra [Wake Forest]) with a 2.5” surface RF coil was used for the assessment.  
187 All data were analyzed using jMURI v7.0 [25]. Magnetic resonance imaging (MRI) was  
188 performed with a 2.5” surface RF coil and used to assess abdominal subcutaneous adipose tissue  
189 (ASAT), visceral adipose tissue (VAT), and quadricep muscle fat infiltration (QFI). The entire  
190 body was scanned and images were analyzed using AMRA Researcher® (AMARA medical AB,  
191 Linköping Sweden) [26].

## 192 **Muscle Biopsy and Mitochondrial Respiration**

193 Muscle biopsy was completed with a Bergström trocar (5 or 6mm) as previously  
194 described [24]. Approximately 10 mg of muscle tissue was allocated for respirometry assays and  
195 were immediately submerged in ice cold BIOPS buffer. Fiber bundles of approximately 2-3 mg  
196 wet weight were gently teased apart and permeabilized as previously described [24] and weight  
197 was measured using an analytical balance (Mettler Toledo, Columbus, OH). Permeabilized fiber  
198 bundle (PmFB) oxygen consumption was measured using a high-resolution respirometer  
199 (Oxygraph-2k, Oroboros Instruments, Innsbruck, Austria). PmFB were placed into chambers  
200 containing MiR05 buffer supplemented with 25 $\mu$ M blebbistatin in the absence of light. Two



201 protocols were completed in duplicate measuring carbohydrate supported (Protocol 1: 5mM  
202 pyruvate and 2mM malate) and fatty acid oxidation (FAO) supported (Protocol 2: 25 $\mu$ M  
203 palmitoyl-carnitine and 2mM malate) respiration. For protocol 1, state 3 respiration was  
204 stimulated with the addition of 4.2mM ADP (OXPHOS<sub>CHO</sub>) followed by subsequent additions of  
205 10mM glutamate and 10mM succinate sequentially (maxOXPHOS<sub>CHO</sub>). Maximal uncoupled  
206 respiration was stimulated with consecutive 0.5 $\mu$ M titrations of 2-[2-[4-(  
207 (trifluoromethoxy)phenyl] hydrazinylidene-propanedinitrile (FCCP) until maximum electron  
208 transport system (ETS) capacity was attained (maxETS<sub>CHO</sub>). For protocol 2, state 3 respiration  
209 was stimulated with the addition of 4mM ADP (OXPHOS<sub>FAO</sub>) followed by subsequent additions  
210 of 10mM glutamate and 10mM succinate to further stimulate mitochondrial complexes I and II  
211 (maxOXPHOS<sub>FAO</sub>). PmFB eliciting an oxygen consumption response <15% were not included in  
212 the final analysis. Respiratory control ratio (RCR) for protocol 1 ( $7.11 \pm 2.86$ ) and protocol 2  
213 ( $3.47 \pm 1.74$ ) were assessed for quality control. Respiration was analyzed using DatLab 7.4.0.4.  
214 In SOMMA, not all participants completed both protocols due to time constraints. Protocol 1  
215 (carbohydrates) was prioritized over Protocol 2 (fatty acids) when limited technician time was  
216 available, which left fewer participants with complete data for Protocol 2.

## 217 **Statistical Analysis**

218 Differences in participant characteristics between older adults with and without diabetes  
219 were compared using the T-test for continuous variables (or Kruskal-Wallis non-parametric test  
220 for skewed variables) and chi-square test for dichotomized variables. Linear regressions without  
221 adjustment were performed to determine differences in cardiorespiratory fitness, and  
222 mitochondrial energetics between those with and without diabetes, and additional adjustments  
223 for the following confounders: age, race, gender, site/technician, BMI, and chronic conditions

224 (model 1). Model 1 was further adjusted for steps per day from ActiPal or volume of adipose  
225 tissue depots: Abdominal Subcutaneous Adipose Tissue (ASAT), Visceral Adipose Tissue  
226 (VAT) and muscle Quadricep Fat Infiltration (QFI). Lastly, to determine the impact of  
227 hypoglycemic medication use within the group of older adults with diabetes, multivariate linear  
228 regression was performed adjusting for age, race, and site/technician. Those analyses were  
229 completed using JMP® Software, Version 16.

230 Linear regression was also used to determine the association of diabetes with walking  
231 speed. We evaluated the potential mediating influence of  $VO_{2peak}$  and/or mitochondrial  
232 energetics. We did this by comparing the beta coefficient for the association of diabetes status on  
233 walking speed from the 400m and 4m walk. The base model included the confounding variables:  
234 gender, age, and race. model 2: base model plus technician and  $maxOXPHOS_{CHO}$ , model 3: base  
235 model plus technician and  $maxOXPHOS_{FAO}$ , model 4: base model plus clinical site and  
236  $VO_{2peak}$ , model 5: base model plus technician,  $VO_{2peak}$  and  $maxOXPHOS_{CHO}$ , model 6: base  
237 model plus technician,  $VO_{2peak}$  and  $maxOXPHOS_{FAO}$ . Fully adjusted models also included the  
238 potential mediators/confounders BMI, and chronic conditions. Finally, we compared the percent  
239 difference in the beta coefficient between the base model and subsequent models to understand  
240 how each adjustment impacted group differences in walking speed. Those analyses were  
241 performed using SAS version 9.4 (SAS institute Inc., Cary, NC).

## 242 **RESULTS**

### 243 **Participant Characteristics**

244 A total of 879 participants (59.2% women) with an average age of  $76.5 \pm 5.0$  years were  
245 enrolled in SOMMA [21]. A summary of participants with available data are included in

246 **Supplemental Figure 1.** Participant characteristics are summarized in **Table 1**. 18% of the  
247 SOMMA cohort were classified as having diabetes. The proportion of women to men was  
248 greater in the group without diabetes ( $p=0.02$ ). The proportion of White participants compared to  
249 non-White was greater in the group without diabetes ( $p<0.001$ ). Older adults with diabetes had a  
250 higher body weight, waist circumference, BMI, and HbA1c (all,  $p<0.001$ ). Individuals with  
251 diabetes tended to have a higher prevalence of heart disease and hypertension, whereas those  
252 without diabetes more often had history of cancer diagnosis ( $p<0.001$ ). Approximately 75% of  
253 participants with diabetes reported use of a hypoglycemic agent where 83% used metformin 19%  
254 used insulin, and 2% used thiazolidinediones (TZD). Total daily steps, and time in MVPA was  
255 significantly lower ( $p<0.001$  for both) and total sedentary time was significantly higher in those  
256 with diabetes ( $p<0.001$ ). Quadriceps muscle fat infiltration (QFI) was higher in those with  
257 diabetes ( $p=0.002$ ). In addition, both abdominal subcutaneous adipose tissue (ASAT) and  
258 visceral adipose tissue (VAT) volume was significantly higher in older adults with diabetes  
259 ( $p=0.005$  for ASAT and  $p<0.001$  for VAT) (**Table 1**).

## 260 **Cardiorespiratory Fitness and Muscle Energetics in Diabetes**

261 In the adjusted model (**Table 2**, model 1 + PA), we report that  $VO_{2peak}$  was  
262 significantly lower in older adults with diabetes compared to those without ( $p= 0.004$ ). State 3  
263 (coupled) respiration in the presence of pyruvate + malate ( $OXP_{CHO}$ ,  $p= 0.12$ ,) and with the  
264 addition of both glutamate and succinate ( $maxOXP_{CHO}$ ,  $p= 0.10$ ) was similar between  
265 groups. Maximal electron transfer system (ETS) capacity measured by maximal uncoupled  
266 respiration with CHO substrates ( $maxETS_{CHO}$ ,  $p=0.03$ ) was significantly lower in those with  
267 diabetes (**Table 2**). State 3 (coupled) respiration in the presence of palmitoyl carnitine + malate  
268 was similar between those with and without diabetes ( $OXP_{FAO}$ ,  $p= 0.10$ ). Maximal oxidative

269 phosphorylation supported by fatty acid substrates ( $\text{maxOXPHOS}_{\text{FAO}}$ ,  $p=0.006$ ) remained  
270 significantly lower in older adults with diabetes in model 1 + PA. Sensitivity analyses completed  
271 in those with data for both Protocol 1 and Protocol 2 had similar results (data not shown) to  
272 ensure that differences between protocols were not due to differences in sample size.

273 Adjustment for levels of QFI, ASAT and VAT did not impact group differences in  
274 mitochondrial energetics and  $\text{VO}_2\text{peak}$  measurements with an exception for  $\text{OXPHOS}_{\text{CHO}}$  (**Table**  
275 **2**). Adjustment for VAT tended to explain some variance in  $\text{OXPHOS}_{\text{CHO}}$  between those with  
276 and without diabetes ( $p=0.06$ , **Table 2**). Within the diabetes group only, ATPmax was lower in  
277 older adults taking any hypoglycemic medication ( $p=0.05$ ) or metformin alone ( $p=0.01$ ,  
278 **Supplemental table 1**). These findings make it difficult to distinguish the impact of medications  
279 versus diabetes on ATPmax and therefore, further analysis of mitochondrial energetics focused  
280 on respiration measurements.  $\text{VO}_2\text{peak}$  and mitochondrial energetics assessed by respiration  
281 were similar with the use of all hypoglycemic agents and metformin (**Supplemental Table 1**).

## 282 **$\text{VO}_2\text{peak}$ and Mitochondrial Energetics Mediate the Relationship between Diabetes and**

### 283 **Walking Speed**

284 Lastly, 400-m and 4-m walking speeds were significantly lower in those with diabetes  
285 compared to those without diabetes following adjustments for gender, age, and race (base model,  
286 **Table 3**). To assess whether  $\text{VO}_2\text{peak}$  and mitochondrial energetics mediated the relationship  
287 between diabetes and walk speed, we compared the  $\beta$  coefficient for mean 400-m and 4-m  
288 walking speed from the base linear regression model with the  $\beta$  coefficient of models that  
289 included  $\text{VO}_2\text{peak}$  and/or mitochondrial energetics variables. Additional individual adjustments  
290 for  $\text{maxOXPHOS}_{\text{CHO}}$  (400-m,  $p=0.02$ , model 2),  $\text{maxOXPHOS}_{\text{FAO}}$  (400-m,  $p=0.02$ ; model 3)  
291 and  $\text{VO}_2\text{peak}$  (400-m  $p=0.01$ ; model 4) resulted in no significant change in group differences in

292 400-m walking speed between those with and those without diabetes (**Table 3**). Alternatively,  
293 for 4-m walking speed, further adjustments for maxOXPHOS<sub>CHO</sub> (4-m, p=0.12; model 2) and  
294 maxOXPHOS<sub>FAO</sub> (4-m, p=0.51, model 3) significantly mediated differences between groups,  
295 whereas VO<sub>2</sub>peak (4-m, p=0.04, model 4) did not. Examining the impact of combinations of  
296 VO<sub>2</sub>peak and mitochondrial energetics revealed that VO<sub>2</sub>peak with maxOXPHOS<sub>CHO</sub> (400-m  
297 p=0.07, 4-m p=0.27; model 5) or maxOXPHOS<sub>FAO</sub> (400-m, p=0.20, 4-m, p=0.99) mediated  
298 differences between those with and without diabetes. Full adjustments including potential  
299 confounders/mediators BMI and chronic conditions explained the remaining variance in walking  
300 speed between groups. (**Table 3**). Comparing the  $\beta$  coefficient for mean 400-m and 4-m walking  
301 speed from the base linear regression model with the  $\beta$  coefficient of models that included both  
302 VO<sub>2</sub>peak and mitochondrial energetics variables revealed that VO<sub>2</sub>peak and mitochondrial  
303 energetics explained an additional ~46-100% of the variance in 400-m and 4-m walking speed  
304 between groups (**Figure 1**).

## 305 **DISCUSSION**

306 In this study of 879 well-phenotyped older adults we found that the 159 participants with  
307 diabetes had slower 4- and 400-m walk speed. We report for the first time that the association of  
308 diabetes status with slow walking speed was mediated by VO<sub>2</sub>peak and skeletal muscle  
309 mitochondrial energetics. We also examined differences in cardiovascular fitness and  
310 mitochondrial energetics between those with and without diabetes while controlling for physical  
311 activity and adiposity. Interestingly, accounting for these potential confounders did not explain  
312 differences in VO<sub>2</sub>peak and mitochondrial respiration between those with and without diabetes,  
313 suggesting other factors may impact cardiorespiratory fitness and energetics in those with  
314 diabetes. We also found that older adults taking hypoglycemic medications (insulin, TZDs,

315 and/or metformin) or metformin alone had significantly lower ATPmax (but not respirometry  
316 measures of mitochondrial energetics) compared to older adults with diabetes but not taking  
317 medications, providing evidence that aligns with reports in the literature that metformin can  
318 impair mitochondrial energetics.

319         The well-phenotyped SOMMA cohort provided an opportunity to assess the impact of  
320 diabetes status on  $VO_2$ peak and mitochondrial energetics in older adults while controlling for  
321 objectively measured indices of physical activity, adiposity, and chronic conditions in addition to  
322 demographic variables. Many of the previous studies reporting lower muscle oxidative capacity  
323 measured in permeabilized fiber bundles from patients with diabetes have not rigorously  
324 assessed and controlled for the participants' physical activity [12-14, 17]. This is important as  
325 physical activity interventions (such as walking) can improve mitochondrial energetics in type 2  
326 diabetes [27] and during weight loss in obesity [28], and in older adults [29]. Here, we report that  
327 lower levels of objectively assessed physical activity partially explains lower respiration in older  
328 adults with diabetes. Interestingly, comparing our respirometry protocols with distinct substrate  
329 combinations, we found that CI+II FAO supported maxOXPHOS respiration remains lower in  
330 the diabetes group, while CI+II CHO only supported maxOXPHOS did not differ following  
331 adjustments for physical activity. This suggests that CHO supported coupled respiration may be  
332 more sensitive to levels of physical activity compared to FAO supported respiration. This is also  
333 in line with evidence indicating reduced rates of lipid oxidation in skeletal muscle from  
334 individuals with diabetes, potentially due to mitochondrial overload and incomplete fatty acid  
335 oxidation [30].

336         The influence of adiposity on mitochondrial energetics has been considered in prior  
337 studies of diabetes, typically by matching control subjects for BMI [14]. Some studies [15, 16],

338 but not all [12, 13, 17], indicate no differences between patients with diabetes and BMI-matched  
339 controls, suggesting that obesity *per se* may underlie the lower muscle oxidative capacity. Here,  
340 we examined the influence that BMI and specific adipose depots (ASAT, VAT, and QFI) had on  
341 muscle mitochondrial energetics in diabetes. However, regardless of whether adiposity was  
342 adjusted for BMI alone or combined with individually objectively measured adipose depots,  
343 mitochondrial respiration generally remained significantly lower in those with diabetes. Taken  
344 together, these findings indicate that adiposity and physical activity largely (there were some  
345 exceptions) do not entirely explain lower mitochondrial energetics in older adults with diabetes.

346 Metformin is one of the most commonly prescribed medications for diabetes, and  
347 although its mechanism of action remains highly debated, there is evidence of an inhibitory  
348 effect on complex I of the electron transport chain [31]. Both pre-clinical and clinical studies  
349 report maladaptation of mitochondrial function following metformin treatment, increased muscle  
350 atrophy and reduced exercise capacity, specifically in older adults [31, 32]. Conversely, others  
351 have reported that metformin can improve mitochondrial function via effects on mitophagy,  
352 autophagy or AMPK activation [33]. Our understanding of how metformin impacts skeletal  
353 muscle mitochondrial function of older adults with diabetes is limited. Here, we reveal lower  
354 ATPmax in older adults with diabetes taking hypoglycemic medication or metformin alone,  
355 compared to older adults with diabetes not taking medications. Interestingly, we did not observe  
356 an association of metformin with diabetes status in the respiration assays, suggesting different  
357 sensitivities to metformin based on whether mitochondrial energetics are assessed *in vivo*  
358 (ATPmax) compared to permeabilized fiber bundle preparations *ex vivo*. However, an important  
359 caveat is that participants were asked to withhold medication prior to the muscle biopsy and  
360 respirometry assays but not on the day of <sup>31</sup>P-MRS assessments. In addition, others have reported

361 no effect on mitochondrial respiration after a two-week metformin treatment compared to control  
362 [34], or in long term diabetes patients [35]. Given that metformin is water soluble, it is also  
363 plausible that the inhibitory effect of metformin is lost when the muscle fiber bundles are washed  
364 in preparation for the respirometry assay. Further work is needed to decipher the impact  
365 metformin has on skeletal muscle mitochondrial energetics in older adults with diabetes.

366 Zhao and colleagues reported that adults with diabetes were 31-34% less likely to  
367 participate in physical activity, which in turn may contribute to lower  $VO_2$ peak [36]. In line with  
368 these reports, SOMMA participants with diabetes were significantly less active and significantly  
369 more sedentary. Our results show that additional adjustments for physical activity did not resolve  
370 differences in  $VO_2$ peak between groups, suggesting that lower  $VO_2$ peak in older adults with  
371 diabetes is independent of physical activity in this cohort. In addition, we report that independent  
372 of adiposity measured by BMI or combined BMI with ASAT, VAT and QFI,  $VO_2$ peak remained  
373 significantly lower in those with diabetes compared to those without. Taken together, our work  
374 suggests that physical activity and adiposity may not be implicated in lower cardiorespiratory  
375 fitness in older adults with diabetes and that other factors including perhaps genetics and  
376 heritability are more important determinants to low cardiorespiratory fitness in diabetes.

377 Previous work from our laboratory and others revealed a significant relationship between  
378 walking speed with both  $VO_2$ peak and mitochondrial energetics in older adults [9, 37, 38]. Here,  
379 we explored the contribution of both mitochondrial energetics and cardiorespiratory fitness to  
380 mobility in older adults with diabetes. We report that mitochondria respiration, both  
381 independently (~40-70%) and combined with  $VO_2$ peak (~55-100%), mediated the variance in 4-  
382 m walking speed in those with diabetes. Differences between groups are further explained by  
383 additional adjustments for potential confounders/mediators BMI, and comorbidities. Reports



384 indicate that muscle mass is lost at an accelerated rate in older adults with diabetes [7],  
385 contributing to reductions in muscle strength and quality [6], and ultimately reducing physical  
386 function and mobility [5, 39]. We extended these findings by highlighting how mitochondrial  
387 energetics may independently and combined with cardiorespiratory fitness also contribute to  
388 lower walk speed in older adults with diabetes. This finding is of particular interest because  
389 slower walking speed is an important indicator of health and has been shown to associate with  
390 survival in older adults [38]. This data raises the possibility that cardiorespiratory physiology and  
391 mitochondrial energetics could be targeted to prevent mobility loss in older adults with diabetes.

392         There are some limitations to the study that should be considered. First, the duration of  
393 diabetes status of SOMMA participants and the length of time that participants have been taking  
394 oral hypoglycemic agents were not recorded. We acknowledge that our study participants were  
395 predominantly (85.6%) non-Hispanic White which limits our ability to generalize to other  
396 race/ethnic groups where mobility disability is more prevalent [40]. In addition, all participants  
397 recruited were able to complete 4-m walk test at a gait speed of greater than or equal to 0.6m/s  
398 and which may be faster than those with more advanced diabetes who are unable to complete  
399 mobility related tasks [2]. Nevertheless, we observe differences in physiological and functional  
400 aspects of skeletal muscle signifying the impact that diabetes has in the SOMMA cohort. The  
401 strengths of our study are the large sample size of participants and rigorous assessment of  
402 objectively measured physical activity, fitness and body composition, and collection of muscle  
403 biopsies for fresh tissue assays.

404         In summary, our findings highlight that mitochondrial energetics independently and  
405 combined with cardiorespiratory fitness contribute to the difference in 400-m and 4-m walk

406 speed in older adults with diabetes. Additionally, future work should aim to decipher the impact  
407 of diabetes medication on mitochondrial function as this remains to be a gap in the literature.

## 408 **ACKNOWLEDGEMENTS**

409 **Personal thanks** - We gratefully acknowledge and thank all participants who participated in this  
410 study at the University of Pittsburgh and Wake Forest University. We acknowledge the dedicated  
411 staff and investigators at both clinical sites as well as at the San Francisco Coordinating Center.  
412 Collection and analyses of <sup>31</sup>Phosphorous Magnetic Spectroscopy data would not have been  
413 possible without the support from Eric Shankland.

414 **Funding and Assistance** – The National Institute on Aging (NIA) funded the Study of Muscle,  
415 Mobility, and Aging (SOMMA; R01AG059416). In part, infrastructure support for SOMMA  
416 was funded by the NIA Claude D. Pepper Older American Independence Centers at the  
417 University of Pittsburgh (Pitt) and Wake Forest University School of Medicine (Wake),  
418 P30AG024827 and P30AG021332 respectively. More SOMMA infrastructure support from the  
419 Clinical and Translational Science Institutes is funded by the National Center for Advancing  
420 Translational Science at both Wake (UL1TR001420). PMCo is supported by R01AG060153 and  
421 R01AG060542. GD was supported by the American Diabetes Association (1-19-PDF-006)  
422 during data collection and analysis.

423 **Conflict of Interest** – SRC and PMCa are consultants to Bioage Labs. PMCa is a consultant to  
424 and owns stock in MyoCorps. All other authors report no conflict of interest.

425 **Author Contributions and Guarantor Statement** – SVR and LYL completed statistical  
426 analysis with final review from the statistical team at the coordinating center. SVR and PMCo  
427 conceived the idea and co-wrote the manuscript. LYL, GD, SM, PMCo and PK completed

428 experiments or completed quality control, validation, and interpretation of data. LYL, GD,  
429 PMCa, PK, TM, SM, MJJ, AJM, EEK, DJM, FGST, SRC, ABN, RTH, SBK, BHG edited the  
430 manuscript. SRC, PMCa, ABN, SBK, RTH, and BHG enabled the study with either funding  
431 acquisition, project administration, and/or conceptualization to the study.

432 **Prior Presentations** – Data from this manuscript has been presented at the following meetings:

433 American Diabetes Association 83<sup>rd</sup> Scientific Sessions May 30<sup>th</sup> - June 6<sup>th</sup> 2022, and the  
434 American College of Sports Medicine Annual Meeting and World Congress, May 30<sup>th</sup> – June  
435 2<sup>nd</sup>, 2023.

436

437 **REFERENCES**

- 438 1. *Centers for Disease Control and Prevention. National Diabetes Statistics Report website.*
- 439 2. Gregg, E.W., et al., *Diabetes and physical disability among older U.S. adults.* Diabetes Care, 2000.  
440 **23**(9): p. 1272-7.
- 441 3. Ryerson, B., et al., *Excess physical limitations among adults with diabetes in the U.S. population,*  
442 *1997-1999.* Diabetes Care, 2003. **26**(1): p. 206-10.
- 443 4. Gregg, E.W., et al., *Diabetes and incidence of functional disability in older women.* Diabetes Care,  
444 2002. **25**(1): p. 61-7.
- 445 5. Volpato, S., et al., *Role of muscle mass and muscle quality in the association between diabetes*  
446 *and gait speed.* Diabetes Care, 2012. **35**(8): p. 1672-9.
- 447 6. Park, S.W., et al., *Decreased muscle strength and quality in older adults with type 2 diabetes: the*  
448 *health, aging, and body composition study.* Diabetes, 2006. **55**(6): p. 1813-8.
- 449 7. Park, S.W., et al., *Excessive loss of skeletal muscle mass in older adults with type 2 diabetes.*  
450 *Diabetes Care,* 2009. **32**(11): p. 1993-7.
- 451 8. Coen, P.M., et al., *Skeletal muscle mitochondrial energetics are associated with maximal aerobic*  
452 *capacity and walking speed in older adults.* J Gerontol A Biol Sci Med Sci, 2013. **68**(4): p. 447-55.
- 453 9. Gonzalez-Freire, M., et al., *Skeletal muscle ex vivo mitochondrial respiration parallels decline in*  
454 *in vivo oxidative capacity, cardiorespiratory fitness, and muscle strength: The Baltimore*  
455 *Longitudinal Study of Aging.* Aging Cell, 2018. **17**(2).
- 456 10. Choi, S., et al., *31P Magnetic Resonance Spectroscopy Assessment of Muscle Bioenergetics as a*  
457 *Predictor of Gait Speed in the Baltimore Longitudinal Study of Aging.* J Gerontol A Biol Sci Med  
458 Sci, 2016. **71**(12): p. 1638-1645.
- 459 11. Newman, A.B., et al., *Walking performance and cardiovascular response: associations with age*  
460 *and morbidity--the Health, Aging and Body Composition Study.* J Gerontol A Biol Sci Med Sci,  
461 2003. **58**(8): p. 715-20.
- 462 12. Phielix, E., et al., *Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo*  
463 *mitochondrial dysfunction in muscle of male type 2 diabetic patients.* Diabetes, 2008. **57**(11): p.  
464 2943-9.
- 465 13. Kelley, D.E., et al., *Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes.*  
466 *Diabetes,* 2002. **51**(10): p. 2944-50.
- 467 14. Mogensen, M., et al., *Mitochondrial respiration is decreased in skeletal muscle of patients with*  
468 *type 2 diabetes.* Diabetes, 2007. **56**(6): p. 1592-9.
- 469 15. Boushel, R., et al., *Patients with type 2 diabetes have normal mitochondrial function in skeletal*  
470 *muscle.* Diabetologia, 2007. **50**(4): p. 790-6.
- 471 16. Larsen, S., et al., *Are substrate use during exercise and mitochondrial respiratory capacity*  
472 *decreased in arm and leg muscle in type 2 diabetes? Diabetologia,* 2009. **52**(7): p. 1400-8.
- 473 17. Schrauwen-Hinderling, V.B., et al., *Impaired in vivo mitochondrial function but similar*  
474 *intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control*  
475 *subjects.* Diabetologia, 2007. **50**(1): p. 113-20.
- 476 18. Distefano, G., et al., *Physical activity unveils the relationship between mitochondrial energetics,*  
477 *muscle quality, and physical function in older adults.* J Cachexia Sarcopenia Muscle, 2018. **9**(2): p.  
478 279-294.
- 479 19. Leite, S.A., et al., *Low cardiorespiratory fitness in people at risk for type 2 diabetes: early marker*  
480 *for insulin resistance.* Diabetol Metab Syndr, 2009. **1**(1): p. 8.
- 481 20. Lee, D.C., et al., *Associations of cardiorespiratory fitness and obesity with risks of impaired*  
482 *fasting glucose and type 2 diabetes in men.* Diabetes Care, 2009. **32**(2): p. 257-62.

- 483 21. Cummings, S.R., et al., *The Study of Muscle, Mobility and Aging (SOMMA). A Unique Cohort*  
484 *Study about the Cellular Biology of Aging and Age-related Loss of Mobility.* J Gerontol A Biol Sci  
485 Med Sci, 2023.
- 486 22. Montoye, A.H.K., et al., *Development of cut-points for determining activity intensity from a wrist-*  
487 *worn ActiGraph accelerometer in free-living adults.* J Sports Sci, 2020. **38**(22): p. 2569-2578.
- 488 23. Balady, G.J., et al., *Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific*  
489 *statement from the American Heart Association.* Circulation, 2010. **122**(2): p. 191-225.
- 490 24. Mau, T., et al., *Mitochondrial energetics in skeletal muscle are associated with leg power and*  
491 *cardiorespiratory fitness in the Study of Muscle, Mobility, and Aging (SOMMA).* J Gerontol A Biol  
492 Sci Med Sci, 2022.
- 493 25. Naressi, A., et al., *Java-based graphical user interface for MRUI, a software package for*  
494 *quantitation of in vivo/medical magnetic resonance spectroscopy signals.* Comput Biol Med,  
495 2001. **31**(4): p. 269-86.
- 496 26. Borga, M., et al., *Reproducibility and repeatability of MRI-based body composition analysis.*  
497 Magn Reson Med, 2020. **84**(6): p. 3146-3156.
- 498 27. Toledo, F.G., et al., *Effects of physical activity and weight loss on skeletal muscle mitochondria*  
499 *and relationship with glucose control in type 2 diabetes.* Diabetes, 2007. **56**(8): p. 2142-7.
- 500 28. Coen, P.M., et al., *Exercise and Weight Loss Improve Muscle Mitochondrial Respiration, Lipid*  
501 *Partitioning, and Insulin Sensitivity After Gastric Bypass Surgery.* Diabetes, 2015. **64**(11): p. 3737-  
502 50.
- 503 29. Pruchnic, R., et al., *Exercise training increases intramyocellular lipid and oxidative capacity in*  
504 *older adults.* Am J Physiol Endocrinol Metab, 2004. **287**(5): p. E857-62.
- 505 30. Kelley, D.E. and J.A. Simoneau, *Impaired free fatty acid utilization by skeletal muscle in non-*  
506 *insulin-dependent diabetes mellitus.* J Clin Invest, 1994. **94**(6): p. 2349-56.
- 507 31. Wessels, B., et al., *Metformin impairs mitochondrial function in skeletal muscle of both lean and*  
508 *diabetic rats in a dose-dependent manner.* PLoS One, 2014. **9**(6): p. e100525.
- 509 32. Konopka, A.R., et al., *Metformin inhibits mitochondrial adaptations to aerobic exercise training*  
510 *in older adults.* Aging Cell, 2019. **18**(1): p. e12880.
- 511 33. de Maranon, A.M., et al., *Metformin modulates mitochondrial function and mitophagy in*  
512 *peripheral blood mononuclear cells from type 2 diabetic patients.* Redox Biol, 2022. **53**: p.  
513 102342.
- 514 34. McKenzie, A.I., et al., *Short-term exposure to a clinical dose of metformin increases skeletal*  
515 *muscle mitochondrial H(2)O(2) emission and production in healthy, older adults: A randomized*  
516 *controlled trial.* Exp Gerontol, 2022. **163**: p. 111804.
- 517 35. Larsen, S., et al., *Metformin-treated patients with type 2 diabetes have normal mitochondrial*  
518 *complex I respiration.* Diabetologia, 2012. **55**(2): p. 443-9.
- 519 36. Zhao, G., et al., *Physical activity in U.S. older adults with diabetes mellitus: prevalence and*  
520 *correlates of meeting physical activity recommendations.* J Am Geriatr Soc, 2011. **59**(1): p. 132-7.
- 521 37. Coen, P.M., et al., *Reduced skeletal muscle oxidative capacity and elevated ceramide but not*  
522 *diacylglycerol content in severe obesity.* Obesity (Silver Spring), 2013. **21**(11): p. 2362-71.
- 523 38. Studenski, S., et al., *Gait speed and survival in older adults.* JAMA, 2011. **305**(1): p. 50-8.
- 524 39. De Rekeneire, N., et al., *Diabetes is associated with subclinical functional limitation in*  
525 *nondisabled older individuals: the Health, Aging, and Body Composition study.* Diabetes Care,  
526 2003. **26**(12): p. 3257-63.
- 527 40. Okoro, C.A., et al., *Prevalence of Disabilities and Health Care Access by Disability Status and Type*  
528 *Among Adults - United States, 2016.* MMWR Morb Mortal Wkly Rep, 2018. **67**(32): p. 882-887.


**Table 1:** Participant Characteristics

<b>Basic Characteristics</b>	<b>Without Diabetes</b>	<b>With Diabetes</b>	<b>p-value</b>
N	717	159	
Age (year)	76.47 ± 5.05	75.79 ± 4.84	0.12
Female	61(438)	51(81)	<b>0.02</b>
Race (white)	88(631)	70(111)	<b>&lt;0.001</b>
Hispanic ethnicity	1(7)	1(2)	0.76
Weight (kg)	74.74 ± 14.75	82.41 ± 15.58	<b>&lt;0.001</b>
Height (m)	1.66 ± 0.10	1.67 ± 0.10	0.16
Waist circumference (cm)	92.69 ± 12.98	100.90 ± 12.57	<b>&lt;0.001</b>
BMI (kg/m <sup>2</sup> )	27.17 ± 4.44	29.55 ± 4.63	<b>&lt;0.001</b>
HbA1c (%)	5.51 ± 0.31	6.73 ± 0.89	<b>&lt;0.001</b>
Systolic blood pressure (mmHg)	129.71 ± 15.80	133.72 ± 16.08	<b>0.004</b>
<b>Co-morbidities</b>			
Lung disease	13(93)	14(22)	0.77
Arthritis	57(409)	52 (83)	0.25
Stroke	2(16)	3(5)	0.51
Heart disease	6(42)	11(18)	<b>0.02</b>
Cancer	43(308)	24(38)	<b>&lt;0.001</b>
Hypertension	26(187)	37(59)	<b>0.006</b>
Kidney disease/renal failure	3(24)	6(9)	0.19
Peripheral vascular disease	1(4)	1(2)	0.37
Hypothyroidism	19(133)	17(27)	0.64
Glaucoma	9(65)	11(18)	0.39
Macular degeneration	9(61)	5(8)	0.12
Cataracts	66(472)	62(99)	0.37
<b>Hypoglycemic Medications</b>			
All	--	75(118)	
• Insulin	--	19(23)	
• Metformin	--	84(99)	
• Thiazolidinediones	--	3(3)	
<b>Physical Activity</b>			
Total daily steps	7066.68 ± 3233.95	5848.70 ± 2791.12	<b>&lt;0.001</b>
Total sedentary time (min)	610.10 ± 112.28	659.40 ± 108.65	<b>&lt;0.001</b>

Time in light physical activity (min)	98.20 ± 26.54	92.84 ± 29.16	<b>0.027</b>
Time in moderate to vigorous physical activity (min)	192.95 ± 86.40	155.66 ± 76.74	<b>&lt;0.001</b>
<b>Body Adiposity</b>			
Abdominal adipose tissue volume (L)	7.50 ± 3.14	8.30 ± 3.31	<b>0.005</b>
Visceral adipose tissue volume (L)	3.96 ± 2.21	5.36 ± 2.31	<b>&lt;0.001</b>
Quadri-cep fat infiltration (%)	0.07 ± 0.02	0.07 ± 0.02	<b>0.002</b>

---

Data presented as means ± standard deviation or % (N). Hypoglycemic medications is calculated only for those taking medications. Significance accepted at **p<0.05** and indicated with bold font.



**Figure 1.** Percent reduction in the association between diabetes and 400-m and 4-m walking speed after adjusting for both individual and combined carbohydrate and fatty acid supported respiration, and cardiorespiratory fitness. Bars depict the reduction in  $\beta$  coefficient from linear regression models (models 2-6 compared to the base model:  $[1 - (\beta_{\text{adjusted}} / \beta_{\text{base adjusted}})]$ ). Base model: age, gender, and race, model 2: base model + maxOXPHOS<sub>CHO</sub>, model 3: base model + maxOXPHOS<sub>FAO</sub>, model 4: base model + VO<sub>2</sub>peak, model 5: base model + VO<sub>2</sub>peak + maxOXPHOS<sub>CHO</sub>, model 6: base model + VO<sub>2</sub>peak + maxOXPHOS<sub>FAO</sub>.



**Table 2.** Cardiorespiratory fitness and mitochondrial energetics in older adults with and without diabetes

Model	Diabetes Status	VO <sub>2</sub> peak	OXPHOS <sub>CHO</sub>	maxOXPHOS <sub>CHO</sub>	maxETS <sub>CHO</sub>	OXPHOS <sub>FAO</sub>	maxOXPHOS <sub>FAO</sub>
Unadjusted	WOD	1532.10 ± 16.67	<b>31.08 ± 0.45</b>	<b>60.63 ± 0.74</b>	<b>81.43 ± 0.97</b>	12.94 ± 0.22	<b>58.22 ± 0.84</b>
	WD	1513.75 ± 36.19	<b>28.10 ± 0.97<sup>#</sup></b>	<b>55.11 ± 1.61<sup>#</sup></b>	<b>73.80 ± 2.11<sup>#</sup></b>	11.93 ± 0.47	<b>53.31 ± 1.78<sup>#</sup></b>
Model 1	WOD	<b>1486.68 ± 19.07</b>	<b>30.14 ± 0.91</b>	<b>59.02 ± 1.45</b>	<b>77.53 ± 1.90</b>	<b>12.58 ± 0.47</b>	<b>59.25 ± 1.64</b>
	WD	<b>1386.69 ± 25.66<sup>*</sup></b>	<b>27.88 ± 1.11<sup>#</sup></b>	<b>54.98 ± 1.80<sup>#</sup></b>	<b>71.25 ± 2.37<sup>#</sup></b>	<b>11.49 ± 0.55<sup>#</sup></b>	<b>54.12 ± 1.93<sup>#</sup></b>
Model 1 + PA	WOD	<b>1487.30 ± 19.53</b>	30.15 ± 0.91	58.65 ± 1.47	<b>77.02 ± 1.98</b>	12.60 ± 0.50	<b>59.21 ± 1.61</b>
	WD	<b>1412.11 ± 26.03<sup>#</sup></b>	28.51 ± 1.11	55.89 ± 1.78	<b>77.83 ± 2.44<sup>#</sup></b>	11.70 ± 0.59	<b>54.29 ± 1.92<sup>#</sup></b>
Model 1 + ASAT	WOD	<b>1492.37 ± 19.52</b>	<b>30.34 ± 0.94</b>	<b>59.50 ± 1.49</b>	<b>77.64 ± 1.95</b>	<b>12.67 ± 0.48</b>	<b>59.83 ± 1.67</b>
	WD	<b>1376.07 ± 26.56<sup>*</sup></b>	<b>27.83 ± 1.15<sup>#</sup></b>	<b>55.07 ± 1.82<sup>#</sup></b>	<b>70.92 ± 2.45<sup>#</sup></b>	<b>11.37 ± 0.57<sup>#</sup></b>	<b>53.85 ± 1.98<sup>#</sup></b>
Model 1 + VAT	WOD	<b>1488.92 ± 19.56</b>	30.16 ± 0.94	<b>59.16 ± 1.49</b>	<b>77.33 ± 1.96</b>	<b>12.62 ± 0.49</b>	<b>59.57 ± 1.68</b>
	WD	<b>1386.86 ± 26.60<sup>*</sup></b>	28.04 ± 1.15	<b>55.46 ± 1.81<sup>#</sup></b>	<b>71.29 ± 2.45<sup>#</sup></b>	<b>11.50 ± 0.57<sup>#</sup></b>	<b>54.66 ± 1.98<sup>#</sup></b>
Model 1 + QFI	WOD	<b>1486.37 ± 19.00</b>	<b>30.28 ± 0.93</b>	<b>59.38 ± 1.48</b>	<b>77.78 ± 1.94</b>	<b>12.68 ± 0.48</b>	<b>59.74 ± 1.68</b>
	WD	<b>1386.10 ± 25.75<sup>*</sup></b>	<b>27.97 ± 1.14<sup>#</sup></b>	<b>55.33 ± 1.81<sup>#</sup></b>	<b>71.06 ± 2.43<sup>#</sup></b>	<b>11.37 ± 0.57<sup>#</sup></b>	<b>54.22 ± 1.98<sup>#</sup></b>


Mean ± standard error with significance accepted at \***p<0.001**, **#p<0.05** and represented with bold font. Model 1 is adjusted for age, race, gender, site/technician, BMI, and comorbidities. PA = physical activity, ASAT = abdominal subcutaneous adipose tissue, VAT = visceral adipose tissue, QFI = muscle quadricep fat infiltration, WOD = without diabetes, WD = with diabetes, OXPHOS<sub>CHO</sub> = carbohydrate supported respiration, maxOXPHOS<sub>CHO</sub> = carbohydrate supported maximal complex I+II stimulated respiration, maxETS<sub>CHO</sub> = carbohydrate supported maximal electron transport system, OXPHOS<sub>FAO</sub> = fatty acid oxidation (FAO) supported respiration, maxOXPHOS<sub>FAO</sub> = fatty acid oxidation supported maximal complex I+II stimulated respiration.


**Table 3: Multivariable linear regression analysis for the association of diabetes with 400m and 4m walk speed**

Multivariable model	Without Diabetes	With Diabetes	
	Means $\pm$ SE	$\beta$ $\pm$ SE	P
<b>400m walk speed (m/sec)</b>			
Base Model: adjusted for gender, age and race	1.06 $\pm$ 0.01	-0.05 $\pm$ 0.01	<b>0.00</b>
Model 2: base model plus maxOXPHOS <sub>CHO</sub>	1.06 $\pm$ 0.01	-0.04 $\pm$ 0.02	<b>0.02</b>
Model 3: base model plus maxOXPHOS <sub>FAO</sub>	1.06 $\pm$ 0.01	-0.04 $\pm$ 0.02	<b>0.02</b>
Model 4: base model plus VO <sub>2</sub> peak	1.07 $\pm$ 0.01	-0.04 $\pm$ 0.01	<b>0.01</b>
Model 5: base model plus VO <sub>2</sub> peak and maxOXPHOS <sub>CHO</sub>	1.07 $\pm$ 0.01	-0.03 $\pm$ 0.02	0.07
Model 6: base model plus VO <sub>2</sub> peak and maxOXPHOS <sub>FAO</sub>	1.07 $\pm$ 0.01	-0.02 $\pm$ 0.02	0.20
Fully adjusted: model 5 plus BMI and comorbidities	1.06 $\pm$ 0.01	0.003 $\pm$ 0.01	0.87
Fully adjusted: model 6 plus BMI and comorbidities	1.06 $\pm$ 0.01	-0.005 $\pm$ 0.02	0.78
<b>4m walk speed (m/sec)</b>			
Base Model: adjusted for gender, age, and race	1.05 $\pm$ 0.01	-0.04 $\pm$ 0.02	<b>0.01</b>
Model 2: base model plus maxOXPHOS <sub>CHO</sub>	1.04 $\pm$ 0.01	-0.03 $\pm$ 0.02	0.12
Model 3: base model plus maxOXPHOS <sub>FAO</sub>	1.05 $\pm$ 0.01	-0.01 $\pm$ 0.02	0.51
Model 4: base model plus VO <sub>2</sub> peak	1.05 $\pm$ 0.01	-0.04 $\pm$ 0.02	<b>0.04</b>
Model 5: base model plus VO <sub>2</sub> peak and maxOXPHOS <sub>CHO</sub>	1.05 $\pm$ 0.01	-0.02 $\pm$ 0.02	0.27
Model 6: base model plus VO <sub>2</sub> peak and maxOXPHOS <sub>FAO</sub>	1.05 $\pm$ 0.01	0.00 $\pm$ 0.02	0.99
Fully adjusted: model 5 plus BMI and comorbidities	1.05 $\pm$ 0.01	0.003 $\pm$ 0.02	0.84
Fully adjusted: model 6 plus BMI and comorbidities	1.05 $\pm$ 0.01	0.01 $\pm$ 0.02	0.50

Without diabetes, mean  $\pm$  standard error. With diabetes,  $\beta$  estimate  $\pm$  standard error with significance accepted at \***p<0.05**.  
maxOXPHOS<sub>CHO</sub> = carbohydrate supported maximal complex I+II stimulated respiration, maxOXPHOS<sub>FAO</sub> = fatty acid oxidation supported maximal complex I+II stimulated respiration. Models including maxOXPHOS<sub>CHO</sub> and maxOXPHOS<sub>FAO</sub> are adjusted for technician, and models with VO<sub>2</sub>peak are adjusted for site.

## Graphical Abstract





**Supplemental Figure 1.** SOMMA cohort sample size for analysis of muscle function, mitochondrial energetics, CRF, PA and body composition. Participants missing data for ex-vivo mitochondrial energetics is due exclusions samples passing quality control. Missing ATPmax measures were due to safety reasons or exclusion due to technical conditions during testing.

**Supplemental Table 1.** Association of hypoglycemic drugs and metformin with cardiorespiratory fitness and mitochondrial energetics

	All hypoglycemic agents		Metformin	
	$\beta$ estimate	p-value	$\beta$ estimate	p-value
VO <sub>2</sub> peak	-82.27 ± 62.24	0.19	-13.08 ± 55.47	0.81
ATPmax	<b>-0.05 ± 0.03</b>	<b>0.05</b>	<b>-0.06 ± 0.02</b>	<b>0.01*</b>
OXPPOS <sub>CHO</sub>	-1.03 ± 2.01	0.61	-0.71 ± 1.81	0.70
maxOXPPOS <sub>CHO</sub>	-3.52 ± 3.20	0.27	-3.11 ± 2.89	0.28
maxETS <sub>CHO</sub>	-2.95 ± 4.45	0.51	-4.07 ± 4.04	0.32
OXPPOS <sub>FAO</sub>	-1.35 ± 1.06	0.21	-0.68 ± 1.00	0.50
maxOXPPOS <sub>FAO</sub>	-2.57 ± 3.69	0.49	-5.30 ± 3.43	0.13

$\beta$  estimate ± standard error with significance accepted at **p<0.05**. Data adjusted for age, race, and site/technician. ATPmax = maximal adenosine triphosphate production, OXPPOS<sub>CHO</sub> = carbohydrate supported respiration, maxOXPPOS<sub>CHO</sub> = carbohydrate supported maximal complex I+II stimulated respiration, maxETS<sub>CHO</sub> = carbohydrate supported maximal electron transport system, OXPPOS<sub>FAO</sub> = fatty acid oxidation (FAO) supported respiration, maxOXPPOS<sub>FAO</sub> = fatty acid oxidation supported maximal complex I+II stimulated respiration.